| Date | Title | Description |
| 24.03.2026 | Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC | Abivax CEO Marc de Garidel told CNBC that the terms of any future deal will be better after it releases data on a key trial in the second quarter.
Intense takeover rumors have surrounded the French biotech company for months, with analysts ... |
| 12.03.2026 | Abivax denies French media report of AstraZeneca takeover | Abivax shares soared on Thursday after a French media report that AstraZeneca was in talks to acquire it.
But a company spokesperson denied the report to CNBC.
Abivax has been the subject of intense takeover speculation for months.
French b... |
| 12.03.2026 | European stocks finish lower as oil prices jump despite reserve release | LONDON — European stocks finished lower on Thursday as investors monitored the Iran war and volatile global oil prices.
The pan-European Stoxx 600 finished the session about 0.7% lower, with underlying sectors painting a mixed picture.
Chem... |
| 12.01.2026 | European markets close higher; Dutch chip stock BESI pops over 7% after posting fourth-quarter prelim order jump of 195% | LONDON — European stocks began the new trading week in positive territory as investors weigh geopolitical developments in Iran, and renewed pressure on Federal Reserve Chair Jerome Powell.
The pan-European Stoxx 600 index preliminarily clos... |
| 09.01.2026 | A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year | Abivax stock rallied in 2025, far outpacing peers, as the French biotech surprised investors with a stellar data readout in July for its lead asset – an ulcerative colitis medicine.
Now, analysts say the French biotech could be bought by a ... |
| 31.12.2025 | European markets close mixed on last trading day of 2025; Defense stocks rose | LONDON — European stocks ended mixed on the last trading day of the year.
The pan-European Stoxx 600 index closed a shortened trading session 0.1% lower on Wednesday, with most sector indexes in negative territory.
The U.K.’s FTSE 100 ended... |
| 23.12.2025 | European markets close at fresh high in final full session before Christmas | LONDON — European markets closed higher on Tuesday, paring the previous session’s losses.
The pan-European Stoxx 600 closed up 0.3%, notching a new record closing high, lifted by surging shares of Copenhagen-listed Novo Nordisk.
That brings... |
| 22.12.2025 | Orsted shares plummet 13% as U.S. pauses 5 offshore wind projects; European markets closed lower | LONDON — European markets moved into negative territory on Monday as last week’s positive sentiment wears off.
The pan-European Stoxx 600 provisionally ended the session 0.1% lower.
It follows a record-breaking previous session where Europe... |
| 16.12.2025 | Europe’s best-performing stock is up 1,400% this year. Here’s what’s next | Abivax shares are up more than 1,400% year to date as investors are optimistic about the prospects of its treatment for ulcerative colitis.
“We are certainly excited about the work we are doing, and we’ve been greeted again by the medical c... |
| 14.11.2025 | Medicxi Closes €500 Million Fund To Advance Asset-Centric Biotech Innovation | Medicxi announced the close of its €500 million Medicxi V vehicle, reinforcing the firm’s position as a major European life sciences investor and adding significant capital to expand its long-standing asset-centric company creation strategy... |
| 22.08.2025 | UK’s FTSE 100 posts best week since May; Europe markets close higher as Fed rate cut hopes mount | European stock markets closed higher on Friday, as investors continued to assess the full scope of the European Union’s trade deal with America and hopes rose for a U.S. interest rate cut in September.
The pan-European Stoxx 600 provisional... |
| 06.08.2024 | Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone | Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the 600-patient enrollment milestone confirming ABTECT cur... |
| 07.02.2024 | Abivax appoints Ana Sharma as Vice President, Global Head of Quality | Abivax appoints Ana Sharma as Vice President, Global Head of Quality
PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry.
While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 13.12.2023 | Sofinnova opens biotech creation ‘toolbox’ as part of Europe-wide strategy | Venture capital firm Sofinnova Partners has launched a new investment strategy specifically aimed at setting up and accelerating biotech startups across Europe.
The strategy, dubbed Biovelocita, will involve a newly formed team assembled wi... |
| 16.11.2023 | 'Optimism' at Jefferies conference, but don't expect biotech IPO boost soon, says Sofinnova chair | When it comes to bringing together pharma and financiers, the U.S. leads the way with industrial-scale events like J.P. Morgan in San Francisco and BIO in San Diego. But for the chairman of European life sciences VC firm Sofinnova Partners,... |
| 23.10.2023 | Abivax Adds $236M to Show Its Anti-Inflammatory Med Can Stand Apart in Crowded Field | Abivax, a company whose ulcerative colitis drug is currently in late-stage clinical development, now has nearly $236 million to continue a pivotal study key to showing not only that its drug works, but also that it can differentiate itself ... |
| 19.04.2023 | Abivax Reports 2022 Financial Results and Operations Update | Obefazimod global pivotal phase 3 program (ABTECT program) in moderate to severe ulcerative colitis (UC) early enrollment progressing according to plan
Abivax reports promising Phase 2b maintenance results with 52.5% of UC patients in clini... |
| 22.02.2023 | Abivax Announces Successful Oversubscribed EUR 130M Cross-Over Financing at Market Price with Top-Tier US and European Biotech Investors | NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR TO U.S. PERSONS
Abivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European biotech investors
This f... |
| 22.02.2023 | Abivax announces successful oversubscribed EUR 130M cross-over financing | - |
| 22.02.2023 | Abivax Announces Successful Oversubscribed EUR 130M Cross-Over Financing at Market Price with Top-Tier US and European Biotech Investors | NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR TO U.S. PERSONS
Abivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European biotech investors
This f... |
| 14.02.2023 | Abivax to Present Blood and Rectal Tissue Data from UC Patients Treated with Obefazimod at the 18th Congress of ECCO | Abivax will be presenting a poster on blood and rectal tissue data from ulcerative colitis (UC) patients, confirming the novel mechanism of action of obefazimod based on the upregulation of a single microRNA, miR-124
The presentation will b... |
| 05.01.2023 | Abivax Publishes Novel Data with Respect to Obefazimod’s Anti-Inflammatory Mechanism of Action | The scientific article in the peer-reviewed journal Clinical and Translational Gastroenterology describes obefazimod's capacity to selectively up-regulate a single microRNA, miR-124, leading to decreases in proinflammatory cytokines and thu... |
| 14.12.2022 | Abivax to Attend the J.P. Morgan 41st Annual Healthcare Conference | Abivax's senior executive management will attend the J.P. Morgan 41st Annual Healthcare Conference and the 12th Annual LifeSci Partners Corporate Access Event from January 9-12 in San Francisco, US
PARIS, FRANCE / ACCESSWIRE / December 14, ... |
| 11.10.2022 | First US Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis | First patient enrolled into the global phase 3 program with obefazimod ("ABTECT-Program") for the treatment of moderate to severe ulcerative colitis (UC) in the US
1,200 UC patients across 36 countries and 600 study centers will t... |
| 02.09.2022 | Abivax announces successful oversubscribed EUR 49.2M cross-over financing | - |
| 16.08.2022 | Abivax Announces a Change in Its Governance | PARIS, FRANCE / ACCESSWIRE / August 16, 2022 / Abivax SA (Euronext Paris:FR0012333284 - ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases,... |
| 10.06.2022 | Abivax Releases the Results of its June 9, 2022 Ordinary Annual and Extraordinary General Meeting | Shareholders approved all proposed resolutions
PARIS, FRANCE / ACCESSWIRE / June 10, 2022 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system t... |
| 18.05.2022 | Abivax Announces Annual Ordinary and Extraordinary General Meeting on June 9, 2022, and the Availability of the Preparatory Documents | PARIS, FRANCE / ACCESSWIRE / May 18, 2022 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral inf... |
| 19.01.2022 | Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022 | DGAP-News: ABIVAX / Key word(s): Study results/Conference
Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022
19.01.2022 / 08:00
The issuer is solely responsible ... |
| 13.01.2022 | Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis | DGAP-News: ABIVAX / Key word(s): Study
Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis
13.01.2022 / 08:00
The issuer is solely responsible for the content of this announc... |
| 15.12.2021 | Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference | DGAP-News: ABIVAX / Key word(s): Conference
Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference
15.12.2021 / 18:30
The issuer is solely responsible for the content of this announcement.
Abivax to present at the J.P. Morga... |
| 01.12.2021 | Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis | DGAP-News: ABIVAX / Key word(s): Study
Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis
01.12.2021 / 19:30
The issuer is solely responsible for the content of this announceme... |
| 30.11.2021 | Abivax's phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium | DGAP-News: ABIVAX / Key word(s): Study results
Abivax's phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Sy... |
| 30.09.2021 | Abivax : announces the release of its half-year financial report 2021 | PARIS, France, September 30, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, ... |
| 30.09.2021 | Abivax : announces the release of its 2021 half-year financial report | DGAP-News: ABIVAX / Key word(s): Half Year Report
Abivax announces the release of its 2021 half-year financial report
30.09.2021 / 18:00
The issuer is solely responsible for the content of this announcement.
Abivax announces the release of ... |
| 28.09.2021 | Abivax : late-breaking abstract presentation and Live Industry Symposium at the UEG Week Virtual 2021 | DGAP-News: ABIVAX / Key word(s): Conference
Abivax late-breaking abstract presentation and Live Industry Symposium at the UEG Week Virtual 2021
28.09.2021 / 18:00
The issuer is solely responsible for the content of this announcement.
Abivax... |
| 28.09.2021 | Abivax : late-breaking abstract presentation and Live Industry Symposium at UEG Week Virtual 2021 | Principal investigator Prof. Séverine Vermeire, M.D., Ph.D, to present Abivax's late-breaking abstract on ABX464 phase 2b study results in ulcerative colitis (UC)
October 4, 2021, at 10:42-10:54 am CEST
Abivax will also be hosting a Live In... |
| 23.09.2021 | Abivax : presents first-half 2021 financial results and operations update | DGAP-News: ABIVAX / Key word(s): Half Year Results
Abivax presents first-half 2021 financial results and operations update
23.09.2021 / 18:00
The issuer is solely responsible for the content of this announcement.
Abivax presents first-half ... |
| 17.08.2021 | Abivax : receives approval for ABX464 phase 1 study in Japanese subjects for subsequent inclusion of Japan into the global phase 3 program in ulcerative colitis | The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approved a phase 1 clinical trial to confirm ABX464's pharmacokinetic profile in Japanese subjects
This phase 1 study is required to include Japan in Abivax's ABX464 global phas... |
| 17.08.2021 | Abivax : receives approval for ABX464 phase 1 study in Japanese subjects for subsequent inclusion of Japan into the global phase 3 program in ulcerative colitis | DGAP-News: ABIVAX / Key word(s): Study
Abivax receives approval for ABX464 phase 1 study in Japanese subjects for subsequent inclusion of Japan into the global phase 3 program in ulcerative colitis
17.08.2021 / 18:00
The issuer is solely re... |
| 23.07.2021 | ABIVAX Societe Anonyme : announces the pricing of its oversubscribed capital increase of EUR 60m and convertible bonds of EUR 25m, totaling eur 85m new financing | DGAP-News: ABIVAX / Key word(s): Capital Increase/Issue of Debt
Abivax announces the pricing of its oversubscribed capital increase of EUR 60m and convertible bonds of EUR 25m, totaling eur 85m new financing
23.07.2021 / 08:00
The issuer is... |
| 23.07.2021 | ABIVAX Societe Anonyme : announces the pricing of its oversubscribed capital increase of EUR 60M and convertible bonds of EUR 25M, totaling EUR 85M new financing | ABIVAX ANNOUNCES THE PRICING OF ITS OVERSUBSCRIBED CAPITAL INCREASE OF EUR 60 M AND CONVERTIBLE BONDS OF EUR 25 M, TOTALING EUR 85M NEW FINANCING
EUR 60M reserved primary equity offering at minimum discount (3%)
EUR 25M convertible bonds pr... |
| 23.07.2021 | PRESS RELEASE : Abivax announces the pricing of its oversubscribed capital increase of EUR 60m and convertible bonds of EUR 25m, totaling eur 85m new financing | DGAP-News: ABIVAX / Key word(s): Capital Increase/Issue of Debt Abivax announces the pricing of its oversubscribed capital increase of EUR 60m and convertible bonds of EUR 25m, totaling eur 85m new financing 2021-07-23 / 08:00 The issuer is... |
| 22.07.2021 | Abivax : announces a capital increase and convertible bonds issue to qualified investors for an aggregate amount of approximately EUR 80M | ABIVAX CAPITAL INCREASE AND CONVERTIBLE BONDS ISSUE TO
QUALIFIED INVESTORS FOR AN AGGREGATE AMOUNT OF
APPROXIMATELY EUR 80M
PARIS, FRANCE, July 22, 2021 - 5:45 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or... |
| 23.06.2021 | Abivax : reports excellent phase 2a clinical safety and efficacy results with 50mg ABX464 in rheumatoid arthritis | ABIVAX REPORTS EXCELLENT PHASE 2A CLINICAL SAFETY AND
EFFICACY RESULTS WITH 50MG ABX464 IN RHEUMATOID
ARTHRITIS
Primary endpoint met with ABX464 demonstrating good safety and tolerability profile with
50mg once daily oral administration
A s... |
| 23.06.2021 | Abivax : reports excellent phase 2a clinical safety and efficacy results with 50mg ABX464 in rheumatoid arthritis | DGAP-News: ABIVAX / Key word(s): Study/Study results
Abivax reports excellent phase 2a clinical safety and efficacy results with 50mg ABX464 in rheumatoid arthritis
23.06.2021 / 08:00
The issuer is solely responsible for the content of this... |
| 24.05.2021 | ABIVAX
Abivax : suspends trading of its shares until the publication of ABX464 Phase 2b results in ulcerative colitis | PARIS, France, May 24, 2021 - 08:00 am (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX) (the 'Company'), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory... |
| 24.05.2021 | ABIVAX
Abivax : reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3 | DGAP-News: ABIVAX / Key word(s): Study results
Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3
24.05.2021 / 18:30
The issuer is solely responsible for t... |
| 24.05.2021 | ABIVAX
Abivax : suspends trading of its shares until the publication of ABX464 Phase 2b results in ulcerative colitis | DGAP-News: ABIVAX / Key word(s): Temporary Suspension
Abivax suspends trading of its shares until the publication of ABX464 Phase 2b results in ulcerative colitis
24.05.2021 / 08:49
The issuer is solely responsible for the content of this a... |
| 30.04.2021 | ABIVAX
Abivax : publishes Universal Registration Document 2021 “Document d'Enregistrement Universel” | PARIS, France, April 30, 2021 - 06:00 p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, v... |
| 30.04.2021 | ABIVAX
Abivax : publishes Universal Registration Document 2021 'Document d'Enregistrement Universel' | DGAP-News: ABIVAX / Key word(s): Miscellaneous
Abivax publishes Universal Registration Document 2021 'Document d'Enregistrement Universel'
30.04.2021 / 18:00
The issuer is solely responsible for the content of this announcement.
Abivax publ... |
| 19.04.2021 | ABIVAX
Abivax : Hosting Key Opinion Leader Webinar on ABX464 for the Treatment of Ulcerative Colitis | DGAP-News: ABIVAX / Key word(s): Miscellaneous
Abivax Hosting Key Opinion Leader Webinar on ABX464 for the Treatment of Ulcerative Colitis
19.04.2021 / 18:11
The issuer is solely responsible for the content of this announcement.
Abivax Host... |
| 14.04.2021 | ABIVAX
Abivax : completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis | DGAP-News: ABIVAX / Key word(s): Study
Abivax completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis
14.04.2021 / 18:30
The issuer is solely responsible for the content of this announcement.
Ab... |
| 14.04.2021 | ABIVAX
Abivax : completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis | 16-weeks induction treatment with ABX464 in phase 2b clinical study in ulcerative colitis completed for the 254 patients enrolled, with reduction of Total Mayo Score after 8 weeks as primary endpoint
Top-line data of induction phase to beco... |
| 31.03.2021 | ABIVAX
Abivax : reports 2020 financial results and operations update | DGAP-News: ABIVAX / Key word(s): Annual Results
Abivax reports 2020 financial results and operations update (news with additional features)
31.03.2021 / 18:00
The issuer is solely responsible for the content of this announcement.
Abivax rep... |
| 31.03.2021 | Abivax : reports 2020 financial results and operations update | DGAP-News: ABIVAX / Key word(s): Annual Results
Abivax reports 2020 financial results and operations update (news with additional features)
31.03.2021 / 18:00
The issuer is solely responsible for the content of this announcement.
Abivax rep... |
| 11.12.2020 | Discussion of Abivax Clinical Program involving Covid-19, Ulcerative Colitis, Crohn’s Disease and more | –COVID-19
Ongoing Phase 2b/3 trial with ABX464 in Covid-19 (miR-AGE trial), the unique properties of the lead candidate (antiviral, anti-inflammatory, tissue repair) to treat elderly and high-risk Covid-19 patients, the rial is ongoing in ... |
| 29.10.2020 | ABIVAX
Abivax : announces the success of its oversubscribed capital increase of EUR 28m at market price | DGAP-News: ABIVAX / Key word(s): Capital Increase
Abivax announces the success of its oversubscribed capital increase of EUR 28m at market price
29.10.2020 / 08:01
The issuer is solely responsible for the content of this announcement.
Abiva... |
| 29.10.2020 | ABIVAX
ABIVAX : ANNOUNCES THE SUCCESS OF ITS OVERSUBSCRIBED CAPITAL INCREASE OF EUR 28M AT MARKET PRICE | ABIVAX ANNOUNCES THE SUCCESS OF ITS OVERSUBSCRIBED CAPITAL
INCREASE OF EUR 28M AT MARKET PRICE
Subscribed by top-tier U.S. and European biotech investors (12 investors in total,
55% of funds raised from European investors, 45% from the U.S.... |
| 14.10.2020 | ABIVAX
Abivax : secures EUR 15m non-dilutive financing from Kreos Capital | PARIS - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces that it has obtained... |
| 13.10.2020 | ABIVAX
Abivax : secures EUR 15m non-dilutive financing from Kreos Capital | • EUR 15m straight bonds, with no associated dilution, favorable financial conditions in interest rates and no expected transaction fees
• Pre-negotiated EUR 5m additional straight bond tranche to be decided
before 2020 year-end
• Cash for ... |
| 13.10.2020 | ABIVAX
Abivax : secures EUR 15m non-dilutive financing from Kreos Capital | DGAP-News: ABIVAX / Key word(s): Bond
Abivax secures EUR 15m non-dilutive financing from Kreos Capital
13.10.2020 / 08:00
The issuer is solely responsible for the content of this announcement.
Abivax secures EUR 15m non-dilutive financing f... |
| 15.02.2019 | ABIVAX Completes €12 Million Capital Raise Entirely Subscribed by Sofinnova Partners at Market Price | Paris, France, 11 July 2019 at 07:30 pm – ABIVAX SA (the “Company” or “ABIVAX”) (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases... |
